Funding for this research was provided by:
Japan Society for the Promotion of Science (JP 20K08730)
Hori Sciences and Arts Foundation
Received: 29 December 2020
Accepted: 9 February 2021
First Online: 18 February 2021
Change Date: 5 March 2021
Change Type: Update
Change Details: The original article has been revised to fix URL and ESM errors.
Ethics approval and consent to participate
: Each hospital’s institutional review board approved the study. Written informed consent was obtained upon treatment and sample collection.
: Not applicable.
: H.K. received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., and Celgene Corporation, consulting fees from Astellas Pharma Inc., Amgen Astellas Bio Pharma K.K., and Daiichi Sankyo Co., Ltd., and honoraria from Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K. These companies are not directly involved in any part of this study. The remaining authors declare no competing financial interests.